According to the global Cancer Gene Therapy market size is expected to surpass around USD 5.9 billion by 2030 from valued at USD 2.4 billion in 2022 and growing at a CAGR of 10.7% from 2022 to 2030.
According to the global Cancer Gene Therapy market size is expected to surpass around USD 5.9 billion by 2030 from valued at USD 2.4 billion in 2022 and growing at a CAGR of 10.7% from 2022 to 2030.
Get the Sample Copy of Report@ https://www.novaoneadvisor.com/report/sample/6789
Cancer gene therapy has gained popularity in the last few years due to its high success rates during clinical and preclinical trials. The emerging field delivers a number of potential applications for cancer treatments. It offers various advances in the field of molecular biology, molecular genetics, immunology, virology, and molecular genetics. In various instances, this technique for cancer has been intended to augment existing therapies, such as immunotherapies and chemotherapies.
The cancer gene therapy approaches include oncolytic virotherapy, immunotherapy, and gene transfer. It can be utilized in different ways. For instance, altering gene regulation, replacing defective and missing genes with healthy genes, and introducing foreign genes into cells to change their function. The most common method is to replace a cancer-causing mutant gene with a healthy one.
Report Scope of the Cancer Gene Therapy Market
|
Report Coverage |
Details |
|
Market Size |
US$ 5.9 Billion by 2030 |
|
Growth Rate |
CAGR of 10.7% from 2022 to 2030 |
|
Largest Market |
North America |
|
Fastest Growing Market |
Asia Pacific |
|
Base Year |
2021 |
|
Forecast Period |
2022 to 2030 |
|
Segments Covered |
Therapy, Indication, Service Provider and Region, |
Viral and non-viral vector products are needed for this technique. Non-viral vectors are normally utilized to transfer the different types of nucleic acids such as large DNA molecules ((Plasmid DNA: p DNA), small DNA, and RNA (m RNA, Si RNA, Ribozymes). Moreover, viral-vector therapies use modified viruses as drug-delivery vehicles to insert specific DNA sequences- regulatory RNAs (e.g. siRNAs), encoding genes, or other therapeutic substrates into cells.
Despite the slow clinical progress, researchers are undertaking efforts to develop specific non-toxic cancer therapies that are rising exponentially. As of now, more than 500 products under trial have been listed with the FDA. There is a number of strategies currently being followed during the cancer treatments. For instance,
- Minimize cancerous cell proliferation and rise cell cycle control by restoring functions such as RB and p53
- Rise in immunological rejection of tumor by the host
The pipeline for cancer therapies is quite strong and various companies are engaged in developing efficient products. Small biopharma companies are also emerging in the cell and gene therapy industry. For instance, Autolus Therapeutics is developing AAV-based gene therapies. The company is targeting patients suffering from chronic, systemic diseases using this technique.
Moreover, improving the regulatory scenario is also expected to increase the product launch in the market. For instance, in March 2021, Bluebird Bio and Bristol Myers Squibb received FDA approval for Abecma (idecabtagene vicleucel). It is a cell-based gene therapy to treat patients with multiple myeloma.
In addition, in February 2022, the University of Pennsylvania doctors’ team announced that cancer patients treated with gene therapy in 2010 shows no sign of cancer in the body. The two examples demonstrate how the therapy, known as CAR-T cell therapy, can fight cancer right away inside the body, and evolve to battle against the tumor. Moreover, in July 2022, ImmunoACT, backed by Laurus Labs, announced that it tested a novel gene therapy cure for leukemia and lymphoma. The lab is working with CD19 CAR-T Cell for leukemia and lymphoma. According to the lab, findings begin to appear after about a week.
Immediate Delivery Available | Buy this Premium Research Report@ https://www.novaoneadvisor.com/report/checkout/6789
Regional Insights
By region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America was the highest Cancer Gene Therapy Market share, with $564.52 million in 2020, and is estimated to reach $4,307.47 million by 2030, registering a CAGR of 22.5% during the forecast period. Owing to significant investments in research and advancements in technology, the Asia-Pacific market is estimated to reach $2,913.67million at a significant CAGR of 24.9%. The presence of a large population base, government initiatives to improve healthcare infrastructure, and an increase in healthcare expenditure are the key driving factors that boost the viral vectors and plasmid DNA market in the region.
Some of the prominent players in the Cancer Gene Therapy Market include:
- Merck KGaA
- Novartis AG
- AstraZeneca Plc.
- BIOCAD
- Crinetics Pharmaceuticals, Inc.
- EffRx Pharmaceuticals S.A.
- Euroscreen S.A.
- Vicore Pharma AB
- Amgen
- Bristol-Myers Squibb
- Cell Genesys Inc.
- Adaptimmune Therapeutics plc.
- Achieve Life Science Inc.
- BioCanCell Ltd.
- Genelux Corporation
- Advantagene Inc.,
- GenVec Inc.
- GlaxoSmithKline PLC
- Amgen Inc.
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Cancer Gene Therapy market
By Therapy:
- Gene Induced Immunotherapy
- Oncolytic Virotherapy
- Gene Transfer
- Others
By Indication:
- Breast Cancer
- Ovarian Cancer
- Liver Cancer
- Pancreatic Cancer
- Lung Cancer
- Prostate Cancer
By Service Provider:
- Hospitals
- Clinical Research Laboratory
- Oncology institutes
Report Objectives
- To define, describe, and forecast the global Cancer Gene Therapy market based on product, technique, methodology, category, and region
- To provide detailed information regarding the major factors influencing the market growth (drivers, restraints, growth opportunities, and challenges)
- To strategically analyze micromarkets1 with respect to individual growth trends, future prospects, and contributions to the overall market
- To analyze the opportunities in the market for key stakeholders and provide details of the competitive landscape for major market leaders
- To forecast the size of the market segments with respect to five main regions—North America (the US and Canada), Europe (Germany, the UK, France, Italy, Spain, and Rest of Europe), Asia Pacific (Japan, China, India, Australia, South Korea, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and the Middle East and Africa
- To profile the key market players and comprehensively analyze their market shares and core competencies2
- To track and analyze competitive developments such as mergers and acquisitions, new product developments, partnerships, agreements, collaborations, and expansions in the global Cancer Gene Therapy market
For Purchase Inquiry@ https://www.novaoneadvisor.com/report/checkout/6789
About Us
Nova One Advisor is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Nova One Advisor has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings.
You can place an order or ask any questions, please feel free to sales@novaoneadvisor.com| +1 9197 992 333